JAN 20, 2021 8:53 AM PST

Screen yourself for colorectal cancer in your own home

Is an at-home colorectal cancer test possible? Researchers from the University of Exeter and the Cancer Research UK CanTest Collaborative certainly think so. According to a study published recently in the British Journal of Cancer, an inexpensive, at-home fecal immunochemical test (FIT) could help rule out colorectal cancer or aid in diagnoses for individuals experiencing low-risk symptoms.

Photo: Pexels

Low-risk symptoms include those such as stomachache, unexplained weight loss, or anemia – in other words, symptoms that could signal colorectal cancer but could also be a sign of many other things. The FIT acts as an early screening tool by detecting traces of blood in the feces samples that individuals collect in the comfort of their own bathrooms.

In conducting this study, 3,890 patients over the age of 50 received the FIT. The test proved to be quite accurate. According to Eureka Alert, “within the group 618 tested positive for blood in their feces, 43 of whom had received a diagnosis of colorectal cancer within 12 months. In the group that tested negative, only eight were diagnosed with colorectal cancer a year later.”

Dr. Joe Mays, of the Peninsula Cancer Alliance, noted: "The rapid and robust analysis has generated the evidence for doctors to use the FIT test with confidence. This led to a reduction in the expected rates of colonoscopy, and helped us build a business case for the ongoing commissioning of this service. Building confidence and familiarity with the test helped us to manage a crisis in endoscopy capacity caused by the COVID-19 pandemic. We're now keen to evidence the performance of the test in higher-risk populations."

Given that this type of test is already used as a colorectal cancer screening for individuals without symptoms, the researchers are excited by the prospect that FIT could play in a healthcare system that is becoming ever more contact-less.

Dr. Sarah Bailey, of the University of Exeter Medical School, adds: "Our findings are very exciting -- we show that this simple and inexpensive test performs exceptionally well in this group of patients with low-risk symptoms, to quickly and accurately tell us who is likely to not have colorectal cancer, and who should be referred for investigation. At a time when hospital services face a backlog as a result of COVID-19 measures, making this decision quickly can ensure the right people are investigated and treated as quickly as possible, which can help save lives. We know that FIT has accelerated interest in how FIT can be used in other patients, such as those with symptoms that have a higher risk of being colorectal cancer and we are now calling for FIT to be evaluated for use across the entire healthcare spectrum, not just in primary care, and in combination with other clinical markers of cancer such as blood test results."

Sources: British Journal of Cancer, Eureka Alert

About the Author
  • Kathryn is a curious world-traveller interested in the intersection between nature, culture, history, and people. She has worked for environmental education non-profits and is a Spanish/English interpreter.
You May Also Like
MAY 19, 2021
Health & Medicine
Who Ages Better, Men or Women?
MAY 19, 2021
Who Ages Better, Men or Women?
The answer depends on what's considered more important – quantity or quality of years?  Previous studies ...
MAY 19, 2021
Cancer
How does environmental quality affect prostate cancer aggressiveness?
MAY 19, 2021
How does environmental quality affect prostate cancer aggressiveness?
A study from researchers at the University of Illinois Chicago investigates the link between environmental quality and p ...
AUG 24, 2021
Technology
CRISPR Helps Identify New Therapeutic Target for Leukemia
AUG 24, 2021
CRISPR Helps Identify New Therapeutic Target for Leukemia
Researchers may have found a new druggable target in patients with acute myeloid leukemia (AML), thanks to a CRISPR scre ...
SEP 02, 2021
Immunology
Hobit Activates Cancer-Killing Immune Cells
SEP 02, 2021
Hobit Activates Cancer-Killing Immune Cells
Innate lymphoid cells, or ILCs, are specialized immune cells that are increasingly entering the research spotlight. Thes ...
SEP 09, 2021
Cancer
Can a Mole Fight Melanoma?
SEP 09, 2021
Can a Mole Fight Melanoma?
About 30% of melanoma cases arise from an existing nevus.  More commonly known as moles, Nevi are skin growths that ...
SEP 16, 2021
Technology
Scientists Create Tiny Replicas Of The Pancreas To Study New Drugs
SEP 16, 2021
Scientists Create Tiny Replicas Of The Pancreas To Study New Drugs
Pancreatic cancer it’s often hard to diagnose in its early stages, resulting in patients having more advanced canc ...
Loading Comments...